To provide a comprehensive synthesis of dual strategies targeting angiogenesis for the treatment of systemic osteoporosis and enhancement of osteoporotic fracture healing, emphasizing their significance.
Key Findings:
Angiogenesis is crucial for bone health and is linked to osteogenesis, with implications for chronic inflammation.
Current osteoporosis therapies are limited in reversing established skeletal deficits.
Enhancing angiogenesis can improve bone repair, density, and alleviate fracture-related pain.
Chronic inflammation in osteoporosis can disrupt angiogenesis and exacerbate bone loss.
Interpretation:
Promoting angiogenesis presents a multifaceted approach to osteoporosis management, potentially improving therapeutic outcomes when combined with conventional treatments, which should be explored further.
Limitations:
Target specificity remains a challenge in angiogenesis-focused therapies.
Translational barriers hinder the application of experimental findings to clinical practice.
There is a lack of robust clinical evidence supporting angiogenesis-targeted interventions.
Potential ethical concerns regarding the use of angiogenesis-targeted therapies.
Conclusion:
A deeper understanding of the vascular-bone axis is essential for developing next-generation therapies aimed at improving bone mineral density and quality in osteoporosis, highlighting the need for future research directions.
